<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01290354</url>
  </required_header>
  <id_info>
    <org_study_id>112867</org_study_id>
    <nct_id>NCT01290354</nct_id>
  </id_info>
  <brief_title>Exploratory Lapatinib (Positron Emission Tomography) PET Study in Subjects With Breast Cancer</brief_title>
  <official_title>An Open-label Positron Emission Tomography Study to Investigate and Quantify Brain and Tumour Penetration of [11C]Lapatinib in Subjects With HER2-overexpressing Breast Cancer</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>GlaxoSmithKline</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>GlaxoSmithKline</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to find out how much lapatinib can enter both normal brains and&#xD;
      brains in which tumours secondary to breast cancer have developed.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Lapatinib is an anti-cancer drug taken by mouth which inhibits the HER2 protein,&#xD;
      overexpressed in some breast tumours. It is not known whether lapatinib passes through the&#xD;
      blood-brain barrier, and, therefore, whether it can target secondary tumours in the brain.&#xD;
      This study will investigate whether lapatinib does indeed enter the brain.&#xD;
&#xD;
      Subjects with HER2-overexpressing breast cancer, with and without brain metastases, will&#xD;
      receive lapatinib tablets daily for 8 days. The subjects will also receive lapatinib with a&#xD;
      small amount of radioactivity attached on the first and last days of dosing to investigate&#xD;
      whether it is taken up by the brain, using positron emission tomography (PET) scans.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">September 12, 2011</start_date>
  <completion_date type="Actual">March 18, 2013</completion_date>
  <primary_completion_date type="Actual">March 18, 2013</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Other</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Brain penetration of [11C]lapatinib</measure>
    <time_frame>8 days</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Brain tumour penetration of [11C]lapatinib</measure>
    <time_frame>8 days</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Safety as assessed by number of subjects with adverse events</measure>
    <time_frame>16-19 days</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>[11C]lapatinib uptake in non-brain tumour sites</measure>
    <time_frame>8 days</time_frame>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">10</enrollment>
  <condition>Cancer</condition>
  <arm_group>
    <arm_group_label>lapatinib</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>unlabelled, administered orally</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Lapatinib</intervention_name>
    <description>Unlabelled, administered orally</description>
    <arm_group_label>lapatinib</arm_group_label>
    <other_name>Tykerb</other_name>
    <other_name>Tyverb</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>[11C] lapatinib</intervention_name>
    <description>Radiolabelled, administered intravenously</description>
    <arm_group_label>lapatinib</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Female, aged &gt;/= 18 years old&#xD;
&#xD;
          -  Advanced or metastatic breast cancer with overexpression of HER2&#xD;
&#xD;
          -  Be able to provide written informed consent and comply with protocol requirements&#xD;
&#xD;
          -  If of child-bearing potential, using adequate and medically acceptable contraception&#xD;
             method&#xD;
&#xD;
          -  Have an ECOG performance status of 0-2 and be in stable condition&#xD;
&#xD;
          -  Able to lie still on the PET scanner for approx. 1.5-2 h&#xD;
&#xD;
          -  Adequate hepatic and renal function&#xD;
&#xD;
          -  Patent ulnar artery or collateral arterial blood vessels&#xD;
&#xD;
          -  If have CNS metastases, disease must be stable&#xD;
&#xD;
          -  Subjects with CNS metastases should have at least a single 1 cm diameter lesion as&#xD;
             shown on contrast MRI&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Subjects with brain metastases who have undergone prior CNS surgery&#xD;
&#xD;
          -  Significant brain abnormalities, neurological disorder, psychiatric disorder or&#xD;
             previous brain damage&#xD;
&#xD;
          -  Diabetes type I&#xD;
&#xD;
          -  History of HIV, hepatitis B or hepatitis C infection&#xD;
&#xD;
          -  Current alcohol and/or drug abuse&#xD;
&#xD;
          -  Positive pregnancy test or lactation&#xD;
&#xD;
          -  Malabsorption syndrome or disease affecting gastrointestinal function that may affect&#xD;
             intestinal absorption&#xD;
&#xD;
          -  Requirement for additional concurrent anti-cancer therapy&#xD;
&#xD;
          -  History of uncontrolled or symptomatic angina&#xD;
&#xD;
          -  Concurrent treatment with an investigational agent or anti-cytotoxic therapy or use&#xD;
             within 30 days or 5 half-lives&#xD;
&#xD;
          -  Known hypersensitivity reaction of idiosyncrasy to drugs chemically related to&#xD;
             lapatinib or its excipients&#xD;
&#xD;
          -  Concurrent treatment with CYP3A4 inducers and inhibitors&#xD;
&#xD;
          -  Unwillingness to refrain from consuming red wine, Seville oranges, grapefruit, pomelo,&#xD;
             grapefruit hybrids and their juices from 7 days before Day 1 until collection of the&#xD;
             final pharmacokinetic sample&#xD;
&#xD;
          -  Known history of claustrophobia&#xD;
&#xD;
          -  Known contraindications or likely risk of toxicity to gadlinium-based MRI contrast&#xD;
             media&#xD;
&#xD;
          -  Presence of cardiac pacemaker, other electronic device or ferromagnetic metal foreign&#xD;
             bodies&#xD;
&#xD;
          -  Any abnormality found on the MRI scan which, in the opinion of the investigator, may&#xD;
             influence the outcome of the PET scans or affect the safety of the volunteer&#xD;
&#xD;
          -  Acute or active hepatic or biliary disease&#xD;
&#xD;
          -  Any medical condition or circumstance making the volunteer unsuitable for&#xD;
             participation in the study.&#xD;
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>GSK Clinical Trials</last_name>
    <role>Study Director</role>
    <affiliation>GlaxoSmithKline</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>London</city>
        <zip>EC1A 7BE</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>London</city>
        <zip>W12 0NN</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>London</city>
        <zip>W6 8RF</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United Kingdom</country>
  </location_countries>
  <verification_date>November 2017</verification_date>
  <study_first_submitted>January 27, 2011</study_first_submitted>
  <study_first_submitted_qc>February 3, 2011</study_first_submitted_qc>
  <study_first_posted type="Estimate">February 7, 2011</study_first_posted>
  <last_update_submitted>November 8, 2017</last_update_submitted>
  <last_update_submitted_qc>November 8, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">November 13, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Brain penetration</keyword>
  <keyword>positron emission tomography</keyword>
  <keyword>Lapatinib</keyword>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Lapatinib</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

